Medical firm hires senior figure to boost US operation

The York-based company has appointed Donald M Hohne as vice president of sales at its US subsidiary, Tissue Regenix USA Inc.

He will work alongside Greg Bila, president of Tissue Regenix USA Inc, to “drive forward” the commercialisation strategy for Tissue Regenix’s dCELL technology platform in North America.

Mr Hohne joins Tissue Regenix USA Inc from Bone Bank Allografts, a distributor of bone and soft tissue allografts, where he has served as director of business development since 2008.

Before that he was director of government affairs at Kinetic Concepts Inc, a global medical technology company where he worked with members of the US Congress to help shape public health policy.

Mr Bila said: “We are extremely pleased to have secured the services of Donald Hohne. He brings with him a proven track record in business development; establishing new market opportunities and securing sales with Fortune 500 and mid-market orthopaedic companies. This is an exciting time for Tissue Regenix USA Inc and Donald will be a key figure in driving forward our strategy for growth.”

Mr Hohne added: “I am delighted to be joining Tissue Regenix USA Inc at the start of the company’s journey. I am excited by the potential possibilities that are presented by the dCELL technology platform which will be a welcome offering for the treatment of a number of diseases and conditions.”

Tissue Regenix established its US subsidiary in November 2012.

In a statement, the company said: “Work is focusing initially on applying the dCELL technology to treat a number of chronic diseases but, over time, it could be developed for other applications including vascular repair, heart valve replacement and knee repair.”

Antony Odell, managing director of Tissue Regenix Group, said: “This is a great time to be welcoming Donald to Tissue Regenix and his appointment represents another significant step in our growth and development. The United States presents an opportunity to establish our dCELL technology platform in a market potentially worth hundreds of millions of dollars, and it is a testament to our proposition that we are able to attract people of Donald’s calibre and experience.”